This CD2-CD58 interaction is crucial for immune ... anti-PD-1 therapy. Efforts to target the CD2-CD58 axis are ongoing in clinical trials. For example, Siplizumab, a monoclonal antibody against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback